Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

GClnc1 as an emerging oncogenic regulator with mechanistic insights and clinical implications in human cancers.

Created on 24 Oct 2026

Authors

Qing Dong, Yixin He, Rui Yu, Xiaochang Gong, Jingao Li, Fangteng Liu

Published in

iScience. Volume 29. Issue 11. Pages 117935. Nov 20, 2026. Epub Oct 16, 2026.

Abstract

Gastric cancer-related long non-coding RNA1 (GClnc1) is an emerging oncogenic regulator in multiple malignancies, including gastric, colorectal, ovarian, and bladder cancers, as well as osteosarcoma. It promotes proliferation, inhibits apoptosis, and enhances drug resistance and metastasis. Mechanistically, GClnc1 dysregulates key cancer-related regulators and pathways, such as p53, MYC, NF-κB, and the SIRT3/SOD2 axis. Clinically, GClnc1 shows diagnostic and prognostic potential across cancers, with aberrant expression in tissues and altered circulating levels. Notably, exosomal GClnc1 serves as a circulating biomarker for early gastric cancer detection and predicts response to fluorouracil-based chemotherapy. This review summarizes current evidence on GClnc1's regulatory mechanisms and discusses its translational applications. GClnc1 may serve as a multi-cancer biomarker and a promising therapeutic target.

PMID:
42920755
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement